CN110621699B - Btla激动剂抗体及其用途 - Google Patents

Btla激动剂抗体及其用途 Download PDF

Info

Publication number
CN110621699B
CN110621699B CN201880033180.XA CN201880033180A CN110621699B CN 110621699 B CN110621699 B CN 110621699B CN 201880033180 A CN201880033180 A CN 201880033180A CN 110621699 B CN110621699 B CN 110621699B
Authority
CN
China
Prior art keywords
ser
leu
val
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880033180.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN110621699A (zh
Inventor
S.K.阿特维尔
V.H.奥班古
A.C.文德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to CN202311364322.XA priority Critical patent/CN117402245A/zh
Priority to CN202311364321.5A priority patent/CN117402244A/zh
Publication of CN110621699A publication Critical patent/CN110621699A/zh
Application granted granted Critical
Publication of CN110621699B publication Critical patent/CN110621699B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880033180.XA 2017-05-19 2018-05-11 Btla激动剂抗体及其用途 Active CN110621699B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202311364322.XA CN117402245A (zh) 2017-05-19 2018-05-11 Btla激动剂抗体及其用途
CN202311364321.5A CN117402244A (zh) 2017-05-19 2018-05-11 Btla激动剂抗体及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508510P 2017-05-19 2017-05-19
US62/508510 2017-05-19
PCT/US2018/032218 WO2018213113A1 (en) 2017-05-19 2018-05-11 Btla agonist antibodies and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202311364322.XA Division CN117402245A (zh) 2017-05-19 2018-05-11 Btla激动剂抗体及其用途
CN202311364321.5A Division CN117402244A (zh) 2017-05-19 2018-05-11 Btla激动剂抗体及其用途

Publications (2)

Publication Number Publication Date
CN110621699A CN110621699A (zh) 2019-12-27
CN110621699B true CN110621699B (zh) 2023-10-31

Family

ID=62245543

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201880033180.XA Active CN110621699B (zh) 2017-05-19 2018-05-11 Btla激动剂抗体及其用途
CN202311364322.XA Pending CN117402245A (zh) 2017-05-19 2018-05-11 Btla激动剂抗体及其用途
CN202311364321.5A Pending CN117402244A (zh) 2017-05-19 2018-05-11 Btla激动剂抗体及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202311364322.XA Pending CN117402245A (zh) 2017-05-19 2018-05-11 Btla激动剂抗体及其用途
CN202311364321.5A Pending CN117402244A (zh) 2017-05-19 2018-05-11 Btla激动剂抗体及其用途

Country Status (26)

Country Link
US (2) US10604573B2 (enExample)
EP (1) EP3625257A1 (enExample)
JP (2) JP6790304B2 (enExample)
KR (3) KR102294051B1 (enExample)
CN (3) CN110621699B (enExample)
AR (1) AR111752A1 (enExample)
AU (2) AU2018269585B2 (enExample)
BR (1) BR112019021547A2 (enExample)
CA (2) CA3184628A1 (enExample)
CL (1) CL2019003215A1 (enExample)
CO (1) CO2019012756A2 (enExample)
CR (1) CR20190521A (enExample)
DO (1) DOP2019000293A (enExample)
EA (1) EA201992460A1 (enExample)
EC (1) ECSP19082184A (enExample)
JO (1) JOP20190261A1 (enExample)
MA (1) MA49133A (enExample)
MX (1) MX381033B (enExample)
MY (2) MY197425A (enExample)
NZ (1) NZ758360A (enExample)
PE (1) PE20191843A1 (enExample)
PH (1) PH12019502575A1 (enExample)
SA (1) SA519410534B1 (enExample)
TW (4) TWI804044B (enExample)
WO (1) WO2018213113A1 (enExample)
ZA (1) ZA201906954B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
GB202008860D0 (en) * 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
IL302135A (en) * 2020-10-23 2023-06-01 Anaptysbio Inc B and t lymphocyte attenuator (btla) modulators and method of using same
MX2024009326A (es) * 2022-01-29 2024-08-06 Hifibio Inc Anticuerpos anti-btla y usos de los mismos en el tratamiento del cancer.
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024243594A1 (en) * 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
EP1560593B1 (en) * 2002-10-25 2016-04-20 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
CA2669921A1 (en) * 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to btla and methods of use
EP2459594A1 (en) * 2009-07-31 2012-06-06 N.V. Organon Fully human antibodies to btla
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
WO2014018931A1 (en) * 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
WO2014183885A1 (en) * 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
JP2018521959A (ja) * 2015-04-29 2018-08-09 サンフォード−バーナム メディカル リサーチ インスティテュート Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション
JP7227007B2 (ja) * 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体

Also Published As

Publication number Publication date
JOP20190261A1 (ar) 2019-11-05
TW201946932A (zh) 2019-12-16
JP2021019642A (ja) 2021-02-18
KR20210106033A (ko) 2021-08-27
AU2018269585B2 (en) 2021-09-02
US20200239578A1 (en) 2020-07-30
AU2018269585A1 (en) 2019-10-31
CN110621699A (zh) 2019-12-27
TWI747043B (zh) 2021-11-21
KR102294051B1 (ko) 2021-08-27
CA3184628A1 (en) 2018-11-22
CL2019003215A1 (es) 2020-04-13
US20180334502A1 (en) 2018-11-22
TW202334237A (zh) 2023-09-01
JP2020518288A (ja) 2020-06-25
MY198277A (en) 2023-08-18
CO2019012756A2 (es) 2020-01-17
KR20220158847A (ko) 2022-12-01
CN117402245A (zh) 2024-01-16
TW201904991A (zh) 2019-02-01
PE20191843A1 (es) 2019-12-31
ZA201906954B (en) 2021-06-30
MY197425A (en) 2023-06-16
MX2019013604A (es) 2019-12-18
MA49133A (fr) 2020-03-25
DOP2019000293A (es) 2019-12-15
EA201992460A1 (ru) 2020-03-18
SA519410534B1 (ar) 2023-11-08
TWI804044B (zh) 2023-06-01
AR111752A1 (es) 2019-08-14
JP6790304B2 (ja) 2020-11-25
ECSP19082184A (es) 2019-11-30
PH12019502575A1 (en) 2020-07-13
BR112019021547A2 (pt) 2020-05-12
KR20190140969A (ko) 2019-12-20
TW202233681A (zh) 2022-09-01
US11396545B2 (en) 2022-07-26
US10604573B2 (en) 2020-03-31
JP7072622B2 (ja) 2022-05-20
CN117402244A (zh) 2024-01-16
CR20190521A (es) 2020-01-06
TWI677504B (zh) 2019-11-21
CA3064518A1 (en) 2018-11-22
MX381033B (es) 2025-03-12
NZ758360A (en) 2022-10-28
EP3625257A1 (en) 2020-03-25
WO2018213113A1 (en) 2018-11-22
AU2021277743A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
CN110621699B (zh) Btla激动剂抗体及其用途
KR102772851B1 (ko) Trem2 항원 결합 단백질 및 이의 용도
CN112513091B (zh) 抗il36r抗体
AU2024200534A1 (en) Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
KR102025848B1 (ko) 항―ｎｇｆ 조성물 및 그의 용도
CN107531783B (zh) 靶向bmp6抗体的组合物和方法
TW202428604A (zh) 結合至ilt4的抗體
TW201023890A (en) Antagonists of IL-6 to prevent or thrombosis
KR20240017912A (ko) 항-ccr8 항체 및 이의 용도
KR20090088950A (ko) 가공된 항-ｔｓｌｐ 항체
CN107207602A (zh) 改良的april结合抗体
CN106795223B (zh) 针对Fcγ受体IIB及Fcε受体的抗体
AU2014226093A1 (en) Anti-TNF-anti-IL-17 bispecific antibodies
AU2013249546A1 (en) Anti-BAFF-anti-IL-17 bispecific antibodies
KR20200067144A (ko) 트랜스타이레틴의 검출 방법
KR20210031722A (ko) 산성 pH에서 VISTA에 결합하는 항체
KR101943724B1 (ko) Ang2 항체
CN111918879B (zh) 用于治疗表达LMA的癌症和自身免疫疾病的抗λ骨髓瘤抗原(LMA)结合蛋白
HK40016006A (en) Trem2 antigen binding proteins and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant